The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Eltrombopag Viatris eltrombopag GenericAdditional monitoring | Viatris Limited | Purpura, Thrombocytopenic, Idiopathic | 🇪🇺 EU 2024-12-12 | Order → |
| Imuldosa ustekinumab BiosimilarAdditional monitoring | Accord Healthcare S.L.U. | Crohn Disease; Psoriasis; Arthritis, Psoriatic | 🇪🇺 EU 2024-12-12 | Order → |
| Theralugand lutetium (177Lu) chloride | Eckert & Ziegler Radiopharma GmbH | Radionuclide Imaging | 🇪🇺 EU 2024-11-22 | Order → |
| Hympavzi marstacimab | Pfizer Europe MA EEIG | Hemophilia A; Hemophilia B | 🇪🇺 EU 2024-11-18 | Order → |
| Fluad influenza vaccine (surface antigen, inactivated, adjuvanted) | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2024-11-15 | Order → |
| Flucelvax influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2024-11-15 | Order → |
| Elahere mirvetuximab soravtansine OrphanAdditional monitoring | AbbVie Deutschland GmbH & Co. KG | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms | 🇪🇺 EU 2024-11-14 | Order → |
| Penbraya meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed) | Pfizer Europe MA EEIG | Meningitis, Meningococcal | 🇪🇺 EU 2024-11-14 | Order → |
| Pomalidomide Teva pomalidomide GenericAdditional monitoring | Teva GmbH | Multiple Myeloma | 🇪🇺 EU 2024-11-14 | Order → |
| Afqlir aflibercept BiosimilarAdditional monitoring | Sandoz GmbH | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion | 🇪🇺 EU 2024-11-13 | Order → |
| Opuviz aflibercept Biosimilar | Samsung Bioepis NL B.V. | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion | 🇪🇺 EU 2024-11-13 | Order → |
| Yuvanci macitentan;tadalafil | Janssen-Cilag International NV | Pulmonary Arterial Hypertension | 🇪🇺 EU 2024-09-27 | Order → |
| Fymskina ustekinumab Biosimilar | Formycon AG | Crohn Disease; Psoriasis; Arthritis, Psoriatic | 🇪🇺 EU 2024-09-25 | Order → |
| Otulfi ustekinumab BiosimilarAdditional monitoring | Fresenius Kabi Deutschland GmbH | Crohn Disease; Colitis, Ulcerative | 🇪🇺 EU 2024-09-25 | Order → |
| Anzupgo delgocitinib Additional monitoring | LEO Pharma A/S | Dermatitis; Eczema | 🇪🇺 EU 2024-09-19 | Order → |
| Axitinib Accord axitinib Generic | Accord Healthcare S.L.U. | Carcinoma, Renal Cell | 🇪🇺 EU 2024-09-19 | Order → |
| Epruvy (previously Ranibizumab Midas) ranibizumab Biosimilar | Midas Pharma GmbH | Wet Macular Degeneration; Macular Edema; Choroidal Neovascularization; Diabetes Complications | 🇪🇺 EU 2024-09-19 | Order → |
| Iqirvo elafibranor OrphanConditionalAdditional monitoring | Ipsen Pharma | Liver Cirrhosis, Biliary | 🇪🇺 EU 2024-09-19 | Order → |
| Ituxredi rituximab BiosimilarAdditional monitoring | Reddy Holding GmbH | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid | 🇪🇺 EU 2024-09-19 | Order → |
| Kayfanda odevixibat Exceptional circumstancesAdditional monitoring | Ipsen Pharma | Pruritus; Alagille Syndrome | 🇪🇺 EU 2024-09-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.